The baseline factors included in the univariable Cox regression analyses for PFS and OS included gender, age, performance status (PS) according to ECOG/WHO (0 vs. 1 and 2), stage (locally advanced vs. metastatic), number of metastasis (0/1/>1), tumor primary (esophagogastric junction vs. stomach), tumor grade (II vs. III), surgery (yes vs. no), platinum agent (cisplatin vs. oxaliplatin), supportive therapy (G-CSF and EPO), adverse events (grade 0/I/II/III, neuropathy, fatigue, anemia, diarrhea). This evidence concerns the gene EPO and neuropathy.